This Medudy course is a conference report for physicians on the topic “63rd ERA Congress 2026 – Key Highlights.”
Prof. Dr. Jörg Latus, Head of the Department of Internal Medicine and Nephrology at Robert Bosch Hospital in Stuttgart, will summarize key study highlights from the conference for you.
This presentation will cover the results of the Phase III FIND-CKD study, which evaluated the efficacy and safety of finerenone as an adjunct to supportive therapy in non-diabetic chronic kidney disease, as well as two studies in the field of IgA nephropathy. These include the final results of the Phase III ALIGN study, which investigated the efficacy and safety of atrasentan in addition to titrated RAS blockade, and a subgroup analysis of the Phase III APPLAUSE-IgAN study evaluating the efficacy and safety of iptacopan.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was created with the kind support of STADA & Otsuka.
By the end of this course, you will know:
– Some of the highlights of ERA 2026
– The key takeaways from the studies presented
– The expert’s conclusion on the studies presented
